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Abstract
Background: Partial protective efficacy lasting up to 43 months after vaccination with the RTS,S malaria vaccine has been
reported in one cohort (C1) of a Phase IIb trial in Mozambique, but waning efficacy was observed in a smaller
contemporaneous cohort (C2). We hypothesized that low dose exposure to asexual stage parasites resulting from partial
pre-erythrocytic protection afforded by RTS,S may contribute to long-term vaccine efficacy to clinical disease, which was not
observed in C2 due to intense active detection of infection and treatment.
Methodology/Principal Findings: Serum collected 6 months post-vaccination was screened for antibodies to asexual blood
stage antigens AMA-1, MSP-142, EBA-175, DBL-a and variant surface antigens of the R29 laboratory strain (VSAR29). Effect of
IgG on the prospective hazard of clinical malaria was estimated. No difference was observed in antibody levels between
RTS,S and control vaccine when all children aged 1–4 years at enrollment in both C1 and C2 were analyzed together, and no
effects were observed between cohort and vaccine group. RTS,S-vaccinated children ,2 years of age at enrollment had
lower levels of IgG for AMA-1 and MSP-142 (p,0.01, all antigens), while no differences were observed in children $2 years.
Lower risk of clinical malaria was associated with high IgG to EBA-175 and VSAR29 in C2 only (Hazard Ratio [HR]: 0.76, 95% CI
0.66–0.88; HR: 0.75, 95% CI 0.62–0.92, respectively).
Conclusions: Vaccination with RTS,S modestly reduces anti-AMA-1 and anti-MSP-1 antibodies in very young children.
However, for antigens associated with lower risk of clinical malaria, there were no vaccine group or cohort-specific effects,
and age did not influence antibody levels between treatment groups for these antigens. The antigens tested do not explain
the difference in protective efficacy in C1 and C2. Other less-characterized antigens or VSA may be important to protection.
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Introduction
GlaxoSmithKlineBiologicals’adjuvantedRTS,Smalariavaccine
candidatehasrepeatedly demonstrated protective efficacy inclinical
trials in Africa [1]. It is composed of the NANP central repeat and
C-terminal T-cell multi-epitope of Plasmodium falciparum circumspor-
ozoite protein (CSP), fused with the S-antigen of hepatitis B virus
and combined withan AS adjuvant systems[2],either AS02 (QS21,
MPL and an oil-in-water emulsion) or AS01 (QS21, MPL and
liposomes) [3]. The RTS,S/AS01 formulation is being evaluated in
a Phase III efficacy trial.
The generation of high titer anti-CSP antibodies has been
extensively documented following RTS,S vaccination of malaria-
naı ¨ve adult volunteers [4]. Although certain antibody thresholds
have been proposed that may be necessary to achieve protection
[5], to date, there is no strict anti-CSP IgG correlate of protection
derived from studies involving laboratory-based challenge of
vaccinated volunteers with the bite of an infectious mosquito.
Additionally, an association has been shown between CSP-specific
CD4+ T cell responses and protection in a laboratory challenge
model [5]. However, information is lacking on immunological
correlates of protection in the face of natural exposure to malaria,
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African field trials of RTS,S have confirmed the consistent, high
titer generation of CSP-specific antibodies, while cell-mediated
immune (CMI) responses have not yet been systematically studied
[6]. Interestingly, in field studies where efficacy against infection is
the primary endpoint, CSP antibodies seemed to correlated with
protection [7,8], whereas no such correlation could be found with
protection against clinical manifestation of disease [7,9], except in
a recent trial of RTS,S/AS02 in infants [10] and a recent analysis
in children vaccinated with RTS,S/AS01 where anti-CSP
antibody titers 6.5 months after vaccination seemed to correlate
with protection [11].
Protection has been observed for up to 43 months following
vaccination despite declining levels of CSP-specific antibodies
[12,13], and efficacy measurements remained remarkably stable.
This long-term protection observed in Mozambican children
differs markedly from the waning protection observed in earlier
studies of RTS,S/AS02 in Gambian men and U.S. non-immune
adults in the U.S. [14,15]. This unexpected finding suggests that,
in addition to anti-CSP antibodies, other factors may contribute to
sustained protection, such as anti-CSP CMI, fine specificity and
functionality of CSP-specific antibodies, or acquisition of blood
stage immunity greater than that which would be acquired
naturally [4]. Indeed, a hypothesis that RTS,S vaccination may
affect blood stage immunity was proposed at earlier stages of this
vaccine’s development [16]. The concept of enhancing naturally
acquired immunity through interventions that reduce the blood
stage parasite burden was proposed to explain long-term efficacy
of intermittent preventive treatment in infants [17]. In the case of
RTS,S vaccination, it was hypothesized that low dose parasitemia
as a result of partial pre-erythrocytic protection may allow for a
more effective immune response to asexual blood stage parasites
[18,19]. The alternative to this hypothesis would be that RTS,S
vaccination reduces naturally acquired immune responses to blood
stage parasites through reduction in high level exposure.
In the Phase IIb trial in children 1–4 years of age performed in
Manhic ¸a, Mozambique, the study was divided into two cohorts,
each with different follow up methods and schedules [7]. Cohort 1
(C1) was followed for 43 months post-vaccination by passive case
detection (PCD) of clinical malaria, and an efficacy of 30.5%
against first or only episode of clinical malaria was observed over
the entire follow-up period [13]. The estimated entomological
inoculation rate in Manhic ¸a District in 2002 was 38 infective bites
per person per year [20]. Cohort 2 (C2) was followed for 6 months
post-vaccination by active detection of infection (ADI) by
fortnightly and monthly household visits and thereafter by PCD;
vaccine efficacy was initially 45.0% against first or only episode of
infection, but waning efficacy was observed by 6 months post-
vaccination. There were no EIR estimates in this area at the time
of the trial, but transmission intensity in C2 was notably higher, as
deduced by elevated blood stage immunofluorescence antibody
test (IFAT) responses at baseline [7]. In addition to transmission
intensity, another key difference was prompt clearing of parasit-
emia during ADI visits in C2, regardless of parasite density or
presence of fever.
Here, we examined the antibody immune responses to multiple
asexual blood stage antigens at 6 months post-vaccination, the
time when waning efficacy is observed in C2 but not in C1. We
hypothesized that in C1, antibodies to asexual blood stage antigens
in the RTS,S/AS02 group would be higher than those in the
control group. Furthermore, we hypothesized that the magnitude
of the difference between C2 vaccine groups would be less than
that observed in C1. We measured antibodies to leading blood
stage vaccine-candidate antigens AMA-1 [21], MSP-142 [22,23]
and EBA-175 [24], as well as variant surface antigens of the R29
P. falciparum culture line (VSAR29) and recombinant DBL-a. The
R29 culture line exhibits high levels of rosetting, and DBL-a is
encoded within var-1 of R29 [25]. Each of these antigens has been
targeted for vaccine development or for further investigation due
to their importance in the blood stage parasite lifecycle, such as
merozoite invasion, immune evasion and cytoadherence [25–27].
Although it is unknown if there is a causal relationship between
antibodies to these antigens and protective immunity, some of
these antibodies have shown association with protection in
seroepidemiological studies [28–30].
Methods
Ethics Statement
The study was approved by the Mozambican National Health
and Bioethics Committee, the Hospital Clı ´nic of Barcelona Ethics
Committee and the PATH Research Ethics Committee, and
written informed consent was gathered from parents/guardians.
Study Design
The samples assessed were obtained as part of a Phase IIb
proof-of-concept randomized, controlled trial of the RTS,S/AS02
vaccine administered to 1–4 year-old Mozambican children
(ClinicalTrials.gov registry number NCT00197041). The trial
design has been described in detail in multiple primary research
articles [7,31,13,19].
Serum samples were obtained from cross-sectional blood
collections at the start of the single-blind phase of follow-up,
corresponding to 6 months after third dose [31,19]. This timepoint
was selected, because it provides a period of 6 months of natural
exposure following vaccination and coincides with the beginning
of the follow-up period where waning efficacy was observed in C2
[19]. Samples were selected to have an equal representation of C1
and C2 and of older and younger children. To do this, samples
were stratified by cohort and by two age groups ($ or ,2 years of
age) to create 4 subgroups of the full sample set. Samples were
randomly selected in each subgroup. Baseline characteristics of the
samples selected, including age group, previous episodes and pre-
vaccination blood stage antibody titers, are given in Table S1.
Recombinant Proteins
Apical membrane antigen 1 (AMA-1) 3D7 strain [21], PfF2
(fragment II of region II of the 175 kDa erythrocyte binding
antigen, EBA-175) [32], and the Duffy binding-like alpha (DBL-a)
domain of PfEMP-1 [25] were produced at ICGEB. FMP009
(FVO strain of AMA-1), FMP1 and FMP010 (3D7 and FVO
strains of MSP-142, respectively) [22,23], all were produced at
WRAIR.
Suspension array technology
Microsphere coupling. A multiplex suspension array
technology (SAT) panel was constructed to quantify IgG responses
to P. falciparum antigens using Luminex xMAP
TM (Luminex Corp.,
Austin, Texas) and the Bio-Plex 100 platform (Bio-Rad, Hercules,
CA). xMAP
TM beads (regions: 4, 10, 15, 34, 40, and 45) were
selected for each antigen. Uncoupled polystyrene 5.6 mmC O O H -
microspheres (Bio-Rad) were coupled to antigen in 200 mLc o u p l i n g
reactions (2.5610
6 microspheres). First, microspheres were washed
twice with 100 mL of Wash Solution from the Bio-Rad carboxylated
microsphere coupling kit. Microspheres were resuspended by
sonication and vortexing and activated using Bead Activation
buffer. Sulfo-NHS (N-hydroxysulfosuccinimide) and EDC (1-Ethyl-
3-[3-dimethylaminopropyl]carbodiimide hydrochloride) (Pierce,
RTS,S Vaccine and Blood Stage Antibodies
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added to reaction tubes at 5 mg/mL each in Bead Activation buffer,
and reaction tubes were incubated at room temperature with gentle
agitation, protected from light for 20 min. Microspheres were
washed with 100 mL PBS, sonicated and vortexed. One microgram
of corresponding recombinant protein per million microspheres was
added to each reaction tube. A prior titration of the antigen
concentrations confirmed that as little as 1 mg of each antigen per
million microspheres could be used without changing the saturation
levels of the microspheres when assayed with hyperimmune plasma
(HIP). Reaction tubes were left at 4u C on a shaker overnight,
protected from light. Microspheres were then blocked with 250 mL
of1%bovineserumalbumin (BSA) inPBSfor 30 min ona shaker at
room temperature, protected from light, then centrifuged and
washed with 500 mL assay buffer (1% BSA/0.05% sodium azide in
PBS, filtered). Coupled microspheres were quantified on a Guava
PCA desktop cytometer (Guava, Hayward, CA), equal amounts of
each analyte combined in multiplex tubes, and stored at 3,000
microspheres/mLa t4 u C, protected from light.
Luminex assay and standard curves. The SAT assay
developed for these analyses used modified standard curves and a
template employed by the Laboratory of Malaria and Vector
Research (LMVR, NIH) ELISA reference center [33]. Briefly,
3,000 microspheres per analyte were added to a 96-well round
bottom plate per well. A HIP pool from Mozambican volunteers
was applied in a 2-fold serial dilution for a starting dilution of
1:1,500 and incubated for 1 h at room temperature with plate
agitation and protection from light. The plate was washed by
pelleting microspheres (centrifuge at 8006g for 5 min) and
resuspended with wash buffer (0.05% Tween 20/PBS). 100 mL
of biotinylated anti-human IgG (Sigma, Tres Cantos, Spain)
diluted 1:2,500 in assay buffer was applied to all wells and
incubated at room temperature for 45 min with agitation and
protection from light. The plate was washed as before, and 100 mL
of streptavidin-conjugated R-phycoerythrin (Invitrogen, Carlsbad,
CA) diluted 1:1,000 in assay buffer was added and incubated at
room temperature for 25 min with agitation and protection from
light. The plate was immediately read using Bio-Plex Manager
version 4.0, and at least 100 microspheres per analyte were
acquired per sample. Crude mean fluorescent intensity (MFI) was
exported with background fluorescence from blank wells already
subtracted. Additionally, Bio-Plex Manager software automatically
calculated the regression equation for the curves of each analyte.
The 5-parameter logistic regression curve with logarithmic
variance weighting was selected due to superior fit with antibody
data [34,35].
y~Az
D
1z x=c
 B  G
where A is the lower asymptote, B is the slope at the inflection
point, C is the concentration at the inflection point, D is the upper
asymptote, and G is a factor of asymmetry.
The back-calculated dilution corresponding to 15,000 MFI,
roughly the middle point of the linear region of a fully saturated
sigmoidal curve with the Bio-Plex 100 system, was assigned the
arbitrary value of 15,000 Antibody Units (AU), and the "undiluted
units" of the HIP pool for each analyte was calculated by
multiplying 15,000 units by the corresponding dilution factor. This
value was registered with the HIP pool to create a reference
standard for these antigens. This reference standard was repeated
on each assay day in a 14-point 2-fold dilution series, starting at a
dilution of 1:1,500 with the corresponding unit values (the large
range of the dilution series encompasses different saturation points
for each antigen). Test plasmas were incubated with the multiplex
microspheres at a final dilution of 1:500 in duplicate, and the assay
was performed as described for the standard curves. Based on the
standard curves for each analyte, AU concentration for each
antigen was calculated by the Bio-Plex Manager software. Samples
where microsphere aggregation exceeded 50% were excluded
from analysis.
Anti-VSA antibody assays
VSA antibody assays were performed as described previously
[36]. The R29 line of P. falciparum was selected for anti-VSA assays
because, compared to other field and laboratory isolates, it was the
most immunogenic in preliminary studies in this population
(Doban ˜o et al. unpublished). Briefly, synchronized cultures of the
R29 line were cryopreserved and thawed for each assay day.
Sterile 96-well round bottom plates were blocked with 200 mL/
well of 1% BSA/PBS and left overnight at 4u C. Erythrocyte
pellets were measured and resuspended in 1% BSA/PBS to 1%
hematocrit, and 95 mL of erythrocyte suspension was added to
each well. A 1:20 dilution, or 5 mL of serum, was added to wells
without replicates, and 4 wells were left as controls: a blank, two
compensation controls and a HIP positive control. Plates were
incubated for 30 min at room temperature with mild agitation and
washed three times by centrifuging the plate at 1,2006g for 2 min,
carefully flicking off the supernatant, and resuspending the pellets
with 200 mL of 1% BSA/PBS. Pellets were resuspended in 100 mL
of polyclonal rabbit anti-human IgG (Dako Cytomation, Glostrup,
Denmark) diluted in 1:200 in 1% BSA/PBS and incubated for
30 min at room temperature with gentle agitation. Plates were
washed and pellets resuspended in 100 mL of Alexa Fluor 488
donkey anti-rabbit IgG (Invitrogen, Carlsbad, CA) diluted 1:1,000
and ethidium bromide (Ecogen, Barcelona, Spain) diluted 1:1,000
from a 1% stock in 1% BSA/PBS and incubated for 30 min at
room temperature with gentle agitation and protection from light.
Plates were washed as before and two additional times with PBS.
Pellets were resuspended in 200 mL of PBS, transferred to
cytometer acquisition tubes containing 200 mL of PBS, acquired
on a 4-color FACS Calibur and analyzed using CellQuest Pro
v5.2.1 (BD, Franklin Lakes, NJ). A gate for infected events was
established using infected erythrocytes and ethidium bromide
stain. A minimum of 1,000 infected events and up to 5,000 were
acquired. Geometric mean MFI was reported for both infected
and uninfected events, and an overall MFI value for specific
VSAR29 antibodies was calculated by subtracting the MFI of
uninfected events from MFI of infected events.
Procedures for normalization of data were as follows. A 6-step
2-fold serial dilution of HIP was added in duplicate to each assay
plate, starting with a 1:20 dilution to generate a reference curve for
inter-assay variation and dynamic assay normalization. A
standardized mean fluorescence intensity (MFI) score was assigned
to each sample, as previously described [37], based on the
hyperimmune plasma (HIP) titration. Samples with specific MFI
above the highest titer (1:20) were assigned a score of 6, between
that and the next titer (1:40) a score of 5, and so forth, and all
samples with specific MFI below the lowest titer (1:640) were given
a score of 0. Additionally, the HIP titrations for all plates were
averaged, and 6 "normalization constants" were generated, one for
each dilution of the HIP, which were the ratio of MFI on the plate
to the mean of all plates. All samples were normalized by
multiplying the crude MFI by the normalization constant
corresponding to the standardized MFI score for that sample
(e.g. a sample with MFI score of 6 would be normalized with the
normalization constant for the 1:20 HIP dilution for that plate).
RTS,S Vaccine and Blood Stage Antibodies
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MFI spectrum than by normalizing all values by a single dilution
of a positive control.
Statistical Analysis
All antibody data were exported in Microsoft Excel, organized
and imported into STATA version 11 (STATA Corp., Texas).
Luminex values were divided by 1,000 for analysis. Data was log-
transformed using the natural logarithm. Differences between
groups were analyzed by the reverse cumulative distribution
function [38] and the Wilcoxon rank-sum test. Correlations
between antibody responses to different antigens were assessed by
Pearson’s correlation coefficient (r), and p-values were adjusted by
the Bonferroni correction. High correlation was considered for
values of r greater than 0.7, and moderate correlation was
considered for r greater than 0.5. Continuous data were analyzed
for variables interacting with antibody levels using an Ordinary
Least Square (OLS) linear regression model adjusting for age
group, cohort, blood stage antibodies at baseline (based on IFAT
performed for the main trial) [7], previous malaria episodes,
present infection and batch of experiments. Interactions with the
vaccine group and the adjusting variables were tested with an F-
test. Data were categorized into 5 groups: below range, lower/
middle/higher tertiles and above range. Categorical data were
analyzed using an Ordered Politomous Logisitc Regression
(OPLR) model adjusting for the same variables as above.
Continuous and categorical data were compared for time-to-first
clinical episode in the single-blind follow-up time period from 6–
18 months post-vaccination [31] using univariate and step-wise
multivariate Cox proportional hazard models on all children,
stratified by cohort and adjusting for vaccine group, age group,
IFAT at baseline, and previous clinical malaria episodes. Maternal
antibodies were not considered as a confounding factor, because
the youngest children in the study were nearly 2 years of age at the
time of sampling. Results were considered statistically significant
for a p-value ,0.05.
Figure 1. Reverse cumulative distribution of crude IgG responses by treatment group. The graphs represent the pooled antibody
responses of children 1–4 years (cohorts 1 & 2 together) who received RTS,S/AS02 vaccine or control vaccine.
doi:10.1371/journal.pone.0025779.g001
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Of the 2022 children aged 1-4 years enrolled, sera from 6
months post-vaccination in 580 randomized individuals who
completed according-to-protocol (ATP) criteria throughout the
single-blind phase (6–18 months post-vaccination) were assayed by
Luminex and flow cytometry. Samples were evenly distributed
between C1 and C2 and between the , 2 years and $2 years age
groups.
Antibody responses in RTS,S and control children
There were no significant differences in the distribution of IgG
responses to any of the antigens tested between RTS,S/AS02
vaccine candidate and control groups in the crude (Figure 1 &
Table S2), or adjusted (Table 1) analyses, and this was the case for
both cohorts separately (Table S3). However, the effect of RTS,S/
AS02 vaccination on blood stage antibodies was different by age
group (Figure 2), with lower IgG levels for the 3D7 and FVO
strains of AMA-1 (p=0.0104 & p=0.0147, respectively) and
MSP-142 (p=0.0009 & p=0.0142, respectively) in the RTS,S
group compared to control, among younger (, 2 years) children
but not in the older ($ 2 years) children (Table 2 & Table S4). No
difference was seen in either age group for antibodies against EBA-
175, DBL-a, or VSAR29.
As previously shown, antibodies were generally higher in the
older age groups, in the region of higher transmission intensity
(C2), in children with previous malaria episodes or infection at the
time of sampling, and in those with higher pre-vaccination IFAT
titers (Table S5).
Correlation of antibody responses to different antigens
Antibody responses to the different antigens were not
systematically correlated (Figure 3). Most antibody combinations
were moderately (15/28) to highly (4/28) correlated. Correlation
was high between AMA-1 3D7 and FVO (r: 0.94, p,0.001) or
MSP-142 3D7 and FVO strains (r: 0.81, p,0.001), indicating high
levels of cross-strain recognition. Prior to performing assays, HIP
was titrated against AMA-1 and MSP-142 3D7- and FVO-coated
microspheres in singleplex and multiplex to confirm a minimal
level of cross-reactivity in the positive control plasma (data not
shown).
Antibody responses in relation to protection from clinical
malaria
We calculated the effect of antibodies at 6 months post-
vaccination on the hazard of clinical malaria, analyzed as
continuous and categorized data. There were no divergences in
the continuous or categorical models, and only the continuous
models are reported here. In C1, there was no evidence of any
association between antibodies and risk of clinical malaria. The
hazard to the first or only episode of clinical malaria was
significantly higher in children with previous malaria episodes
(hazard ratio [HR]: 2.95, p,0.001), and lower in the older age
group of children (HR: 0.54, p=0.015). In C2, there was a lower
risk of clinical malaria associated with higher IgG to EBA-175 and
VSAR29 (Table 3 & Table S6), as well as a lower risk in the older
age group (HR: 0.57, p=0.041). The HR was, again, significantly
higher in children with previous malaria episodes (HR: 1.91,
p=0.004).
Discussion
We tested a hypothesis that vaccination of children with the
partially protective, pre-erythrocytic stage RTS, S adjuvanted
vaccine candidate would elicit a broadly stronger asexual blood
stage immune response that may be associated with long-term
protection from clinical disease. Furthermore, we proposed that
this observation would explain the waning efficacy observed in C2
and in newborns [8,12]. From the onset, we were confronted with
the question of which antigens to select among the nearly 2,000
antigens of the asexual blood stage (www.plasmodb.org). Our
selection was limited by the current knowledge and availability of
blood stage antigens, and we used targets expressed on the surface
of merozoites or infected erythrocytes, thus accessible to the
immune system and probably under immune pressure [39], and
which have known functions in erythrocyte invasion, immune
evasion and cytoadherence.
No differences were observed in the distribution of antibodies to
AMA-1 (3D7 & FVO), MSP-142 (3D7 & FVO), EBA-175, DBL-a
and VSAR29 when comparing all children in the RTS,S/AS02
and control vaccine groups, suggesting that RTS,S/AS02 neither
enhances nor impairs antibodies naturally acquired against blood
stage antigens. This finding contrasts with a recent report on blood
stage antibodies in a Phase IIb trial of RTS,S in Kenya and
Tanzania, which found a significant reduction in blood stage
antibodies in RTS,S-immunized children [40]. However, when
stratifying by age, AMA-1 and MSP-142 antibodies were lower in
the RTS,S/AS02 group in children ,2 years of age at enrollment.
In this case, the results from Bejon et al. agree with ours, given that
the ages of all children in that trial were below 2 years of age [9].
The reduction in episodes of malaria and, thus, exposure to
parasites afforded by RTS, S/AS02, thereby reduces levels of IgG
to some blood stage antigens, particularly antigens shown to be
markers of exposure [41–43]. The absence of a detectable
reduction in the older age group may be explained by the
relatively high antibody levels already acquired in these children;
reduced exposure in the RTS, S group may have a less dramatic
effect on these antibody levels.
The hypothesis that waning efficacy in C2 is a result of
interrupted exposure to low dose parasitemia hinges on a
differential profile of blood stage antibodies from those of C1,
which is not supported by these data. One explanation is that these
antigens may merely serve as strong markers of exposure, which is
Table 1. Multivariate linear regression model showing the
effect of RTS,S vaccination on levels of IgG to blood stage
antigens, compared to control vaccination, adjusted by
cohort, age, IFAT titer at baseline, batch of experiments,
previous episodes and present infection.
Antigen Prop. Diff
a 95% CI
b pR
2c
AMA-1 (3D7) 0.82 0.61–1.10 0.190 0.63
AMA-1 (FVO) 0.90 0.66–1.24 0.525 0.62
MSP-142 (3D7) 0.97 0.72–1.32 0.867 0.48
MSP-142 (FVO) 0.87 0.64–1.18 0.365 0.34
EBA-175 1.08 0.83–1.41 0.547 0.38
DBL-a 1.13 0.91–1.40 0.258 0.43
VSAR29 1.07 0.87–1.33 0.502 0.49
aProportional difference refers to the proportional effect per log-increase in
antibody level.
bConfidence Interval.
cR
2 value of the OLS regression model was ,0.65 in all cases, indicating that
only a portion of the variability of IgG data is explained in the model.
doi:10.1371/journal.pone.0025779.t001
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antigens tested were higher in C2 and may indicate an already
advanced level of blood stage immunity, where RTS,S gives less
impact on blood stage antibodies. Lower antibodies in younger
children may also be linked to exposure. Whereas blood stage
antibodies to AMA-1 and MSP-142 in older children may have
already reached a plateau, partial pre-erythrocytic protection
afforded by RTS,S may reduce the levels of antibodies to antigens
Figure 2. Reverse cumulative distribution of antibodies in RTS,S/AS02 vaccine vs. control vaccine groups, stratified by age group.
The graphs represent the pooled antibody responses (cohorts 1 & 2) who received RTS,S/AS02 vaccine or control vaccine.
doi:10.1371/journal.pone.0025779.g002
Table 2. F-test for interactions between RTS,S vaccine group and key variables on antibody levels.
Prop. Diff.
a (95% CI) ,2 years Prop. Diff.
a (95% CI) .2 years p-value interaction RTS,S x Age group
AMA-1 (3D7) 0.51 (0.32–0.81) 1.11 (0.76–1.63) 0.0104
AMA-1 (FVO) 0.55 (0.34–0.91) 1.23 (0.82–1.84) 0.0147
MSP-142 (3D7) 0.52 (0.33–0.82) 1.46 (0.98–2.17) 0.0009
MSP-142 (FVO) 0.54 (0.34–0.87) 1.17 (0.79–1.74) 0.0142
Results are proportional difference in antibody levels associated with being in the RTS,S/AS02 vaccine group.
aProportional difference refers to the proportional effect per log-increase in antibody level to blood stage antigens; CI: Confidence Interval.
doi:10.1371/journal.pone.0025779.t002
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We have no evidence that these lower levels of antibodies in
younger RTS,S-vaccinated children result in an impairment of
blood stage immunity over the 43 months of follow-up. Further
studies should confirm this result. The difference in transmission
intensity between cohorts remains a potential factor in vaccine
efficacy that cannot be controlled in these data, but which may
explain the waning efficacy observed in C2 through potential
mechanisms such as increased likelihood of inoculation, greater
exposure to parasite genetic diversity and a higher level of
challenge to strain-specific or variant-specific naturally acquired
immunity.
Interestingly, children with higher IgG to EBA-175 and VSAR29
at 6 months post-vaccination had a lower hazard of clinical
malaria up to 18 months, but this result was only observed in C2.
We found that vaccine group did not modify antibody levels to
these antigens differently in C1 and C2, thus showing no
interaction between vaccine group and cohort and suggesting that
protection in C1 may be mediated by other immune factors. It is
possible that the children living in Ilha Josina (C2) experience a
faster build-up of immunity than those living in Manhic ¸a (C1) due
to the differences in transmission intensity, perhaps indicating a
more ‘‘mature’’ immune response in C2. This is supported by the
clinical patterns of disease in these populations [44], where the age
pattern of disease is shifted to earlier age in Ilha Josina, compared
to Manhic ¸a (Aide et al., Guinovart et al., in preparation). It follows
that affinity maturation of antibodies in C2 may also occur earlier
than in C1 and account for differences in the protective effect of
the antibodies. Thus, further characterization of the antibodies
evaluated here, particularly fine specificity [45], subclasses of IgG
[29], affinity and/or avidity [46] and in vitro functional capacity,
could show further differences, both between cohorts and in
prospective risk of disease.
Could other asexual blood stage antigens be more relevant to
immunity? Evidence from a study in Mali before and after the
transmission season suggests that a number of previously
uncharacterized antigens may be better candidates for discrimi-
nation of protection from clinical disease [47]. A broader
repertoire of antibody responses is shown to be associated with
reduced risk of clinical malaria [48]. Anti-VSA antibodies and,
particularly, how rapidly they are acquired in succession, may be
important factors in parasite control [49]. The moderate
correlation between antibodies against different antigens suggests
that the selection may not be representative of the blood stage
antibody immune response as a whole, and that different antibody
levels could be expected within individuals for other antigens. It
remains to be seen if these antibodies are acquired differently in
RTS,S-vaccinated versus control-vaccinated individuals.
In conclusion, antibodies to the immunodominant blood stage
antigens evaluated here were neither higher nor lower in RTS,S-
immunized children compared to the control vaccine group, as a
whole. In younger children, there seemed to be a reduction in
Figure 3. Correlation of antibody responses to merozoite and VSA antigens within the individual. A matrix of log-transformed antibody
units or mean fluorescence intensities (VSAR29) against the selected blood stage antigens shows correlation of antibody responses between antigens.
Pearson’s correlation coefficient (r) is included in each antibody combination panel (p-value,0.001 for all correlations).
doi:10.1371/journal.pone.0025779.g003
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there is no evidence in this study that these lower antibody levels
translate to an impairment of naturally acquired immunity. Based
on our findings, antibodies to the common blood stage antigens
tested do not explain the difference in long-term efficacy between
C1 and C2. The data are not sufficient to reject the hypothesis that
the RTS,S vaccine facilitates immunity upon exposure to blood
stage parasites, as it is not known if the antigens selected are
representative of, or relevant to, the overall protective antibody
response of asexual blood stage antigens, and CMI responses were
not addressed. Further characterization of naturally acquired
blood stage antibodies must be done for the duration of the follow-
up period to highlight protective antibody responses and effects of
RTS,S vaccination in these two cohorts.
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